In this episode of "Larvol & Friends", Luca Dezzani, an MD and seasoned executive in the pharmaceutical industry, discusses the future of medical affairs in 2023. Dezzani shares his insights on how medical affairs will evolve to become more integrated with commercial and research functions, as well as how technology will play an increasingly important role in supporting medical affairs activities. This episode provides a thought-provoking look at the changing landscape of medical affairs and how it will impact the pharmaceutical industry in the near future.

In this episode, join our host & CEO Bruno Larvol and Sarah Snyder, a pharmacist and renowed Medical Affairs recruiter, to discuss the role of Digital Opinion Leaders (DOLs) in 2023. The conversation delves into the evolving landscape of influencer marketing and the impact of DOLs in shaping public opinion and driving consumer behavior. Snyder provides valuable insights into the strategies and best practices for effectively partnering with DOLs to amplify brand messaging and engage target audiences. This episode sheds light on the importance of transparency, authenticity, and ethical considerations when leveraging DOLs as influential voices in the digital realm. Give it a listen to delve deeper into a captivating exploration of the power and influence of DOLs in the contemporary digital marketing landscape!

On this episode of “LARVOL & Friends”, we invite Darko Medin, a prominent figure in AI-driven cancer research and Biostatistics/Bioinformatics Data Science consultant, to examine the dynamic intersection of AI and oncology.  

We explore how AI is revolutionizing cancer diagnosis, treatment personalization, and research, while considering the challenges and ethical implications that arise. A must-listen for anyone interested in the future of cancer care and the transformative power of artificial intelligence.

In this episode of "LARVOL & Friends", host Bruno Larvol chats with health innovation and patient care expert Gil Bashe about the future of medicine and the role of AI innovation in driving change. From AI-powered diagnostics to personalized medicine, the two explore the latest trends and breakthroughs in healthcare innovation. With insights from his years of experience working with healthcare companies and advocacy groups, Bashe offers a visionary outlook on the future of healthcare and highlights the challenges we face to improve our daily well-being with the use of virtual reality. Whether you're a healthcare professional or simply interested in cutting-edge of medical technology, this episode is for you!

In this compelling episode of "LARVOL & Friends", we're joined by Neneh Vannitamby, MD, medical writer and an expert in clinical research and diversity. We delve into the critical topic of ethnic diversity in clinical trials, discussing its importance for improving treatment efficacy and minimizing health disparities. Vannitamby shares her insights on the challenges to achieving diversity in trials and possible solutions. Essential listening for anyone interested in equitable healthcare and the future of clinical research.

On this episode of “LARVOL & Friends”, we welcome Patrina Pellet, Medical Affairs expert and a leading voice in pharmaceutical strategy, as we explore the vital role of Key Opinion Leaders (KOLs) in the pharma industry. 

Pellet breaks down how KOLs influence drug development, medical education, and healthcare policy, offering insights into the challenges and ethical considerations of managing KOL relationships. A must-listen for those interested in the behind-the-scenes dynamics of the pharmaceutical world.

This episode of LARVOL & Friends features Yamina Hakem, CEO and founder of Global Reach BI and a pioneer in pharmaceutical competitive intelligence. 

We delve into the landscape of competitive intelligence in 2023, discussing its role in guiding strategic decision-making in the pharmaceutical industry. Hakem shares her insights into the latest tools, strategies, and challenges in the field. An essential episode for professionals seeking to gain a competitive edge in the rapidly evolving pharma sector.